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Abstract
Purpose To explore whether the symptoms of climacteric
syndrome associated with its physical factors or psycholog-
ical disorder in perimenopausal/postmenopausal patients
with anxiety–depression disorder.
Methods We recruited 78 climacteric patients with anxi-
ety–depression disorder and 72 control participants in peri-
menopausal/postmenopausal without anxiety–depression
disorder for this study. We measured symptoms using the
Greene Climacteric Symptom Scale in all cases. We also
collected demographic data and tested sexual hormone,
blood pressure, bone density, cognitive, estrogen receptor-
alpha (ER) gene polymorphism as physiological factors,
using HARS-14 and CHDS assessed psychological disor-
der degree.
Results C-MMSE scores as well as Estradiol and proges-
terone levels in the anxiety–depression disorder group were
signiWcantly lower compared to the control group
(P < 0.01). In addition, the anxiety–depression disorder
group had signiWcantly higher Greene Climacteric Scale
scores, as well as somatic symptoms compared to controls
(P < 0.01). Moreover, the anxiety, depression and somatic
symptoms of the Greene Climacteric Scale were positively
correlated with HARS-14 and CHDS scores (P < 0.001)
and negatively with estrogen level and C-MMSE scores
(P < 0.05) in the anxiety–depression disorder group.
Greene Climacteric Scale Symptoms were not signiWcantly
correlated with blood pressure, bone density or other fac-
tors (P > 0.05). There was no signiWcant change in the
allele frequency or the estrogen receptor-alpha gene poly-
morphisms, between the two groups (P > 0.05); however,
the Pp genotype was negatively associated with C-MMSE
scores (r =a p p r a i s e s ,   P = 0.033).
Limitations The sample size was relatively small.
Conclusions The symptoms of somatic symptoms in
patients with climacteric syndrome and anxiety–depression
disorder are associated with the emotional disorder but not
with a physical disease. The Pp ER polymorphism Pvu II
is associated with a cognitive decrease.
Keywords Climacteric · Anxiety–depression · Somatic 
symptoms · Cognitive · Physical disease
Introduction
Women in perimenopausal or postmenopausal, with the
gradual degradation of ovarian function in the female hor-
mone decreasing, can appear some physiological and psy-
chological aspects of symptoms, main performance: hot,
sweaty, tired, headache, dizziness, numb, sore limbs, atten-
tion poor, anxious and nervous, insomnia, mood swings, and
sorrow depression, clinical called “menopause syndrome” or
“climacteric syndrome” [1,  2]. Depression or anxiety or
depression combined anxiety (anxiety–depression) is a com-
mon psychological disorder in menopausal women. In
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SWAN 2010, 18% of elderly women had psychological dis-
orders [3], and anxiety–depression in addition to have major
depression, dropping interest, outside self-evaluation, anxi-
ety, nervousness, tendency to get angry, and also may be
associated with fatigue, insomnia, inattention, memory loss,
pain and so on menopause syndrome-like symptoms. Two
diseases have common some syndromes characteristic (espe-
cial somatic syndrome) easily confused in clinic, but also
have diVerence risk for healthy. Although emotional disor-
ders occur frequently in climacteric syndrome, climacteric
syndrome that severely compromises life and work is rare. In
contrast, anxiety–depression disorder has serious risk for
women [4]. On the other hand, decline in the health of
patients (e.g., hypertension and osteoporosis) often accompa-
nies mild cognitive dysfunctions [5, 18, 20]. Some patients
are excessively concerned about their health and visit clinics
frequently, which can lead to many misdiagnoses and waste
medical resources [6, 7]. Do these patients have multisystem
symptoms resulted from somatized anxiety–depression disor-
der or from truly organic diseases?
Reports on syndromes characteristic patients with anxi-
ety–depression disorder in perimenopausal are limited. Are
the multisystem symptoms of patients with anxiety–depres-
sion disorder in perimenopausal/postmenopausal as severe
as their psychological ones? This question needs to be
investigated further. Estrogen receptor (ER) polymor-
phisms are associated with many disorders including Alz-
heimer’s disease (AD), osteoporosis and coronary heart
disease [8–11]; however, little is known about the associa-
tion between ER polymorphisms and anxiety–depression
comorbid with climacteric syndrome. In this study, we ana-
lyzed ER polymorphisms, sex hormone levels, psychologi-
cal symptoms, cognitive function, blood pressure, bone
density, menopausal transition (MT) stages and diseases
course based on the Greene Climacteric Scale categories
[12]. This study would be to recognise syndromes charac-
teristic and provide the theoretical base for the early diag-
nosis of depression or anxiety in perimenopausal/
postmenopausal.
Methods
Participants and sampling
Based on our study aim and requirements for statistical
analyses, between 2007 and 2010, we recruited over 78
patients with anxiety and depression in perimenopausal and
postmenopausal, as well as control participants with cli-
macteric syndrome only. Concerning menopausal status we
used the following deWnitions: perimenopausal women
having irregular menses, less than 12 menses during the last
12 months and postmenopausal: no more menses in the last
12 months. All participants meet the Stages of Reproduc-
tive Aging Workshop (STRAW) criteria for peri/postmeno-
pause, MT score of STRAW be ¡1 to +2 [2], combined
with at least one symptom of climacteric syndrome. The
age range of this sample was 40–60 years old. Exclusion
criteria of All participants undergoing hormonal therapy,
hormone therapy by implant in the preceding 6 months,
endocrinopathies leading to menstrual irregularities, hepat-
opathies, thrombopathies, use of drugs which interfere in
the menstrual cycle, anxiolytics and antidepressants (as
their use indicates previous diagnosis of mood disorders),
hysterectomy, oophorectomy, cancer or psychiatric disease
or other severely organic diseases. This study was approved
by the institutional review board of the Third AYliated
Hospital of Guangzhou Medical College (Guangzhou,
China) and written informed consent was obtained from
every participant.
We placed participants in the anxiety–depression group
using the anxiety and depression diagnosis standard listed
in ICD-10 [13]. The criteria include the following: (1) use
of the Hamilton Anxiety Rating Scale-14 items (HARS-14)
[14, 15] and the Chinese version of the 17-item Hamilton
Depression Rating Scale (CHDS) [16], all patients HARS-
14 scores ¸14 and or CHDS ¸17; (2) experience of major
anxiety symptoms for at least 3 months or major depression
symptoms for at least 2 weeks; and (3) decline in function-
ing at work and home. Using these standards, we recruited
78 patients with major anxiety and or depression symptoms
as anxiety–depression group, of whom 58 had mixed anxi-
ety and depression disease(MADD, ICD-10 code F41.2),
13 of whom had anxiety only (ICD-10 code F41.8) and 7 of
whom had depression only (ICD-10 code F32.0).The aver-
age age of these patients was 52.14 § 5.74 years. Although
somatization disorder is a somatoform disorder that over-
laps with a number of functional somatic syndromes and
has high comorbidity with major depression and anxiety
disorders [17]. The study anxiety–depression patients were
not coincided with somatization or somatization form dis-
order diagnosis criterion (ICD-10 code F45.0, F45.1).
Procedure
We recorded patient demographic information including age,
education, disease course and menopausal status. Education
level was deWned as time spent in school. Disease course was
deWned as the duration of their symptoms in years; a disease
course of over 6 months was considered to be 1 year. Meno-
pause was deWned as the cessation of menses for over
12 months according to SRTAW [2]. The early postmeno-
pausal cases was 26 (33.33%) and 28 (38.89%) in anxiety–
depression group and control group. There were no diVerence
between them (P < 0.01). We used the HARS-14 and CHDS
to determine anxiety and depression levels [14–16].Arch Gynecol Obstet (2012) 285:1345–1352 1347
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The Greene Climacteric Scale
We analyzed the characteristics of climacteric syndrome
based on the Greene Climacteric Scale. In 2010, the valida-
tion and reliability of Greene Climacteric Scales (validation
0.68–0.76, reliability 0.83–0.87 in Chinese population) was
reported by Zheng et al. in HongKang. The Greene Clima-
teric Scale measures a total of 21 symptoms (Table 1)
[12,  18]. Each symptom is rated by the woman herself
according to its current severity using a four-point rating
scale: not-at-all symptoms (0); a little symptoms (1); quite a
bit symptoms (2); extreme symptoms (3). The Greene Cli-
macteric Scale scores include 21 items scores and an individ-
ual score within Wve symptom clusters: (1) anxiety symptoms
(symptoms 1–6), (2) depression symptoms (symptoms
7–11), (3) somatic symptoms (symptoms 12–18), (4) vaso-
motor symptoms (symptoms 19–20) and (5) sexual func-
tion (symptoms 21). The mean score for each symptom is
calculated by the sum of all individual scores divided by the
number of subjects. The mean score of each symptom
clusters are the mean scores of the symptoms within that
cluster.
The organic diseases diagnosis was based on the 2007
ESH-ESC (European Society of Hypertension-European
Society of Cardiology) Practice Guidelines [19], the 2009
Osteoporosis Guidelines [20, 21] and the standard for early
detection of dementia, including mild cognitive impairment
[22], blood pressure, poor recognition ability and low bone
density. Our study used the Chinese Mini Mental State
Examination (C-MMSE) [23, 24] to assess the patient rec-
ognition function and the Fan Beam X-ray Bone Densitom-
eter to assess bone density. We measured real-time blood
pressure over 24 h to calculate patients’ average systolic
and diastolic measurements.
Sexual hormone determination
We measured estradiol (E2), progesterone and testosterone
levels using radioactive immunoassays. Peripheral vein
blood was collected between 7:00 and 8:00 am. Blood from
non-menopausal women were collected 3 days after their
menstrual cycles. The variation of estradiol, progesterone
and testosterone levels within anyone group was 5.6, 7.2
and 8.01%, respectively. The diVerences of estradiol, pro-
gesterone and testosterone levels between the groups were
6.5, 7.8 and 8.5%, respectively. The sensitivity of each
ELISA assay was 0.01, 0.001 and 0.0001 pg/ml, respec-
tively.
The analysis of polymorphisms in ER genes, PvuII 
and XbaI primer design and synthesis
The sequence for the estrogen receptors is as follows: P1:
5-CTGCCACCCTATCTGTATCTTTTCCTATTCTCC-3;
Table 1 Greene Climacteric 
Scale score comparisons 
between the anxiety–depression 
group and the control group 
(x § s)
Groups Anxiety–depression 
group (n =7 8 )
Control 
group (n =7 2 )
1. Heart beating quickly or strong 1.14 § 0.78a 0.56 § 0.6
2. Feeling tense or nervous 1.42 § 0.86a 0.63 § 0.54
3. DiYculty in sleeping 1.33 § 0.81a 0.58 § 0.65
4. Excitable 1.31 § 0.86a 0.37 § 0.47
5. Attacks of panic 0.74 § 0.82a 0.21 § 0.35
6. DiYculty in concentrating 1.11 § 0.81a 1.02 § 0.62
7. Feeling tired or lacking in energy 1.56 § 0.83a 0.38 § 0.4
8. Loss of interest in most things 1.05 § 0.90a 0.25 § 0.32
9. Feeling unhappy or distressed 1.20 § 0.86b 0.86 § 0.51
10. Crying spells 0.85 § 0.90a 0.18 § 0.36
11. Irritability 1.32 § 0.93a 0.47 § 0.5
12. Feeing dizzy or faint 1.42 § 0.99a 0.52 § 0.38
13. Pressure or tightness in head or body 1.23 § 0.89a 0.25 § 0.31
14. Parts of body feel numb or tingling 1.21 § 0.85a 0.52 § 0.45
15. Headaches 1.41 § 0.91a 0.98 § 0.62
16. Muscle and joint pains 1.27 § 0.92a 0.85 § 0.49
17. Loss of feeling in hands or feet 0.44 § 0.70a 0.24 § 0.34
18. Breathing diYculties 0.59 § 0.76a 0.18 § 0.27
19. Hot Xashes 0.85 § 0.88b 1.29 § 0.91
20. Sweating at night 0.74 § 0.77b 1.06 § 0.81
21. Loss of interest in sex 0.85 § 0.88 0.78 § 0.61 Using a Chi-square test 
a P < 0.01, b P <0 . 0 51348 Arch Gynecol Obstet (2012) 285:1345–1352
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and P2: 5-TCTTTCTCTGCCACCCTGGCGTCGATTAT
CTGA-3. In descending order, the DNA molecular weight
(Mark Shenzhen, Yishengtang Biological Enterprises Ltd.)
of these receptors are 2,000 bp/1,600 bp/1,200 bp/800 bp/
600 bp/400 bp/200 bp.
The method for genotyping estrogen receptors uses three
steps. (1) Whole genomic DNA was extracted using the fast
extraction method. (2) A polymerase chain reaction (PCR)
where the total reaction estrogen receptor volume was
50 L and comprised 34.3 L sterile deionized water, 5 L
10£ PCR buVer, 200 mol/L dNTP 4 L, 40 pmol primers,
100 ng DNA template and 1 U TaqDNA polymerase. Reac-
tion conditions consisted of a denature step at 94°C for
3 min, followed by 35 cycles of 94°C for 30 s, 61°C for
40 s, 72°C for 90 s, and a Wnal extension at 72°C for 5 min.
The extension product size was 1.3 kb. (3) Finally, a
restricted enzymatic reaction was performed using 6 U
PvuII and 10 U XbaI for enzymatic digestion, followed by
a 1.2 agarose gel with ethidium bromide electrophoresis for
40 min, which was then photographed.
Two professional psychologists tested patients’ neuro-
logical and psychological statuses. Prior to these tests, both
psychologists were trained to adjust and unify their stan-
dards.
Statistical analysis
All data were recorded as mean § standard deviation
(x § s). We used SPSS 17.0 software for all statistical
analyses. (1) ANOVA and ANCOVA rank-sum tests
(i.e., variance arrhythmias) analyzed the demographic
and symptomatic diVerences between the anxiety–depression
group and the control group. (2) Pearson’s correlation ana-
lyzed the relationships between symptoms, psychological
scores and physiological status. (3) Chi-square tests ana-
lyzed the frequency of estrogen receptor-alpha polymor-
phisms. (4) Multifactorial logistic analyses analyzed the
relationship between the ER polymorphism and other
symptoms such as sex hormone levels, psychological
scores (HARS-14 and CHDS) and cognitive functions. A
P value of less than 0.05 was considered signiWcantly
diVerent.
Results
DiVerences in demographic information, HARS-14, 
CHDS, C-MMSE, Greene Climacteric Scale scores 
and sexual hormone levels between groups
As shown in Table 1, there were signiWcant diVerences
between the anxiety–depression group and the control
group (P < 0.001) in all areas except diYculty in concen-
trating and sexual interest. The vasomotor symptoms scores
as well as the facial redness and evening sweating scores
for the anxiety–depression group were signiWcantly lower
(P < 0.05) compared to the control group; all other anxiety–
depression group scores were higher than the control group
(P < 0.01). As shown in Table 2, the Greene climacteric
Scale scores of anxiety, depression and somatic symptoms
were signiWcantly higher in the anxiety–depression
group (P < 0.001) compared to control group, although
the vasomotor symptoms scores were signiWcantly lower
(P < 0.05). The HARS-14 and CHDS scores of the anxiety–
depression group were signiWcantly higher than the control
group (P < 0.001) whereas the E2 and progesterone levels
were signiWcantly lower (P < 0.001). The cut-oV score for
the statistics in Table 2 is 27 (mild cognitive diYculty [21].
An ANCOVA rank sum test (variance arrhythmias) showed
that the C-MMSE score in the anxiety–depression group
was signiWcantly lower than the control group (P <0 . 0 1 ) .
There were no signiWcant diVerences in age, testosterone
level, bone density, systolic and diastolic blood pressure
between the two groups.
Correlation analysis between Greene Climacteric Scale 
symptoms with general condition, psychological score, 
bone density, average blood pressure in anxiety–depression 
disorder group
As shown in Table 3, Pearson’s correlational analyses,
revealed positive correlations between Greene Climacteric
Scale anxiety, depression and somatic symptoms scores
with HARS-14 and CHDS scores (P < 0.001) as well as
negative correlations between E2 and progesterone levels
and C-MMSE scores (P < 0.05) within the anxiety–depres-
sion group. There was also a positive correlation between
education years in the anxiety–depression group. There was
an additional correlation between vasomotor symptoms and
HARS-14 scores, whereas sexual factors were correlated
with CHDS scores (P < 0.05). There was no signiWcant cor-
relation between Greene Climacteric Scale scores and
blood pressure, bone density, menopause, disease course or
other factors (P >0 . 0 5 ) .
Polymorphism analyses on the ER gene
We used P, pX or x to indicate restriction enzymes. Lower-
case letters indicated the digestion sites of the enzyme,
whereas capital letters indicated the absence of restricted
enzyme sites. The PvuII restriction enzyme distinguishes
between three genotypes: PP (1.3 kb), Pp (1.3 kb +
850 bp + 450 bp) and pp (850 bp + 450 bp). The XbaI
restriction enzyme distinguishes between three genotypes:
XX (1.3 kb), Xx (1.3 kb + 910 bp + 390 bp), and xx
(910 bp + 390 bp; Fig. 1)Arch Gynecol Obstet (2012) 285:1345–1352 1349
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ER gene polymorphisms and the allele frequency 
distribution
Table 4 shows the allele frequency of the ER Pvu II and
Xba polymorphisms. The allele frequencies of the studied
sample were consistent with the Hardy–Weinberg Genetic
equations and representative populations. The genotype
distribution in the anxiety–depression group was
PP17.95%, Pp39.74%, pp42.31%, XX10.26%, Xx32.50%
and xx57.69%. The allele frequency for P and X is 37.81
and 26.28%, respectively. Both groups have a majority of p
and x gene sites. As shown in Table 4, there were no sig-
niWcant diVerences between the anxiety–depression and
control groups in the genotypes of the ER PvuII or Xba I
polymorphisms.
The correlation between ER gene polymorphisms 
and anxiety–depression symptoms
One-way factorial analyses indicated that the Pp and pp
genotypes were correlated with anxiety, depression,
and organic diseases, as well as CHDS, HARS-14 and
C-MMSE scores. The xx genotype was correlated only
with organic disease and vasomotor symptoms. When we
introduced the ten factors above into a multifactorial logis-
tic model, only the Pp genotype and C-MMSE scores were
negatively correlated (y = 4.51 £ 1.043 ¡ 2.22, r = ¡0.108,
95% CI 0.014 » 0.883, P = 0.033).
Table 2 Comparison of Greene 
Climacteric Scale, HARS-14, 
CHDS, and C-MMSE scores, as 
well as sexual hormone levels, 
bone density and average blood 
pressure (x § s)
Groups Anxiety–depression 
group (n =7 8 )
Control 
group (n =7 2 )
P value
Age (years) 52.14 § 5.74 51.55 § 4.87 0.576
Education (years) 8.95 § 2.63b 10.57 § 3.67 0.010
Disease time of anxiety and 
depression (years)
4.18 § 3.41 0 /
HARS-14 score 16.42 § 9.32a 5.54 § 2.73 0.000
CHDS score 15.4 § 8.02a 4.6 § 1.86 0.000
C-MMSE score 26.97 § 1.88a 28.92 § 0.72 0.000
E2 (pg/ml) 133.63 § 161.32a 304.83 § 248.64 0.000
Testosterone (pg/ml) 0.89 § 0.33 1.12 § 0.21 0.143
Progesterone (pg/ml) 4.68 § 10.08a 15.34 § 27.00 0.000
Whole body bone density 1.022 § 0.119 1.024 § 0.109 0.738
BlAv Mean systolic pressure (mmHg) 140.94 § 21.59 138.48 § 15.29 0.681
Average diastolic pressure (mmHg) 80.78 § 13.65 78.96 § 10.81 0.127
Anxiety symptoms 1.19 § 0.52a 0.56 § 0.35 0.000
Depression symptoms 1.21 § 0.61a 0.41 § 0.37 0.000
Somatic symptoms 1.09 § 0.54a 0.57 § 0.59 0.000
Vasomotor symptoms 0.83 § 0.70b 1.12 § 0.84 0.025
Sexual function symptoms 0.85 § 0.89 0.78 § 0.61 0.452 Using a Chi-square test, 
a P < 0.01, b P <0 . 0 5
Table 3 Correlation analysis between the Greene Climacteric Scale
symptoms with general condition, psychological score, bone density
and average blood pressure in anxiety–depression disorder group
Variations
Correlation factors Co-eYcient P value
Anxiety symptoms
Education years 0.235 0.039
E2 ¡0.371 0.001
Progesterone ¡0.310 0.007
HARS-14 0.795 0.0001
CHDS 0.791 0.0001
C-MMSE ¡0.343 0.002
Depression symptoms
E2 ¡0.249 0.028
HARS-14 0.560 0.0001
CHDS 0.613 0.0001
C-MMSE ¡0.242 0.033
Somatic symptoms
E2 ¡0.325 0.004
HARS-14 0.639 0.0001
CHDS 0.711 0.0001
C-MMSE ¡0.380 0.001
Vasomotor symptoms
HARS-14 0.227 0.046
Sexual factors
CHDS 0.262 0.0201350 Arch Gynecol Obstet (2012) 285:1345–1352
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Discussion
Our study shows that HARS-14, CHDS and Greene Cli-
macteric Scale scores of anxiety, depression and somatic
symptoms were signiWcantly higher in perimenopausal/
postmenopausal patients with anxiety–depression disorder
compared to a control group, whereas E2 and Progesterone
levels were signiWcantly lower (P < 0.01). These Wndings
indicate that, in addition to anxiety and depression disor-
ders, somatic symptoms are characteristics of climacteric
patients with anxiety–depression disorders. This Wnding is
also consistent with a previous report using Greene Climac-
teric Scale results [25, 26]. Using a Pearson’s correlation
analysis, we found that a decreased E2 level is correlated
with anxiety, depression and somatic symptoms, which in
turn might be correlated with the onset of anxiety–depres-
sion disorder. Previous work by other researcher corrobo-
rates this Wnding [27, 28]. Additionally, our study indicates
that anxiety, depression and somatic symptoms are corre-
lated with psychological scores but not with blood pressure,
bone density, menopause or disease course. These Wndings
indicate the following: (1) the Greene Climacteric Scale is
valid for determining climacteric patients with anxiety and
depression disorders; and (2) the somatic symptoms in cli-
macteric patients with anxiety–depression disorders might
be correlated with emotional disorders only [28, 29] and
not with organic diseases, such as hypertension and osteo-
porosis.
The anxiety–depression group showed a signiWcant
decrease in vasomotor symptoms, which is positively corre-
lated with the HARS-14 score. This result is inconsistent
with our other Wndings. Based on the symptoms of patients
with anxiety–depression disorder, our study shows that
there is correlation between vasomotor symptoms and the
occurrence of anxiety disorders. Patients with light anxiety
may keep their symptoms hidden, whereas patients with
severe anxiety may show vasomotor. However, patients
with anxiety–depression disorder showed a signiWcant
decrease in vasomotor symptoms, indicating that these
symptoms may be characteristic of climacteric syndrome.
Seritan and others have shown that vasomotor symptoms in
patients with climacteric syndrome are closely associated
with psychological status [28, 30]. Although we sampled
patients with climacteric syndrome and anxiety–depression
disorder, our results are consistent with previous Wndings.
A recent report has shown that the somatic symptoms in cli-
macteric syndrome might be the accumulative eVect of anx-
iety and facial redness, which is also consistent with our
observations [29].
Our study found a correlation between education level
and anxiety and depression symptoms, indicating that peo-
ple with more education are more likely to be anxious dur-
ing menopause. This Wnding is inconsistent with the study
by Kakkar et al. [1]. We did not Wnd a signiWcant change in
sexual interest in the anxiety–depression group compared
to the control group; this Wnding is also not consistent with
the SWAN report. Asian attitudes toward sex-related issues
tend to be conservative, which could explain our results.
There seems to be no change in the sexual interest of
patients with anxiety and depression. Moreover, our study
Fig. 1 Left the endonuclease 
PvuII distinguished three geno-
types: PP (1.3 kb), pp 
(850 bp + 450 bp) and Pp 
(1.3 kb + 850 bp + 450 bp). 
Right the Endonuclease Xba I 
gene distinguished three 
genotypes: Xx 
(1.3 kb + 910 bp + 390 bp), 
xx (910 bp + 390 bp) and XX 
(1.3 kb)
Table 4 The analysis of ER Pvu II genotypes and allele frequencies
Using a Chi-square analysis, we found no signiWcant diVerences between the two groups in the six genes (2 = 0.66–1.65, P >0 . 0 5 )
Groups PvuII restriction enzyme genotype (%) Allele (%) XbaI restriction enzyme genotype (%) Allele (%)
PP Pp pp P p XX Xx xx X x
Anxiety–depression 
group (n =7 8 )
14 (17.95) 31 (39.74) 33 (42.31) 37.81 62.19 8 (10.26) 25 (32.50) 45 (57.69) 26.28 73.72
Control group (n = 72) 15 (20.83) 34 (47.22) 23 (31.90) 44.44 55.56 11 (15.27) 26 (36.11) 35 (48.61) 33.33 66.67Arch Gynecol Obstet (2012) 285:1345–1352 1351
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indicated that sexual behavior is negatively correlated with
depression scores, which is consistent with previous Wnd-
ings [3, 31].
The transcription factor of ER is located in the cytosol
and nucleus and includes two isoforms: ER and ER.
Human ER is located on the 6q24–27 gene [8] and
includes eight exons and seven introns, at a total length of
140 kb. In the Wrst ER gene intron, we found a T to C
mutation at 0.4 kb upstream of the second exon, and an A
to G mutation 50 bp downstream of the locus, resulting in
the restriction sites for PvuII and XbaI, respectively, thus
creating a restriction site polymorphism [8,  9]. Previous
studies have shown that the ER gene polymorphism is cor-
related with hot Xashes and vaginal dryness but not with
emotional disorders in patients with climacteric syndrome
[32].
Our study indicates that the allele distribution of anxi-
ety–depression genotypes is PP17.95%, Pp39.74%,
pp42.31%, XX10.26%, Xx32.50% and xx57.69%. The
allele distribution frequency for the P and X alleles is 37.81
and 26.28%, respectively. The majority of alleles are p and
x. Statistical analysis revealed no signiWcant diVerences in
the genotypes of the ER PvuII and XbaI genes. Moreover,
there was no correlation between the ER allele and anxiety
or depression symptoms. This Wnding is consistent with
Malacara [32]. Based on a multifactorial logistic analysis,
there is a negative relationship between the Pp genotype in
the ER gene and the C-MMSE score in the anxiety–
depression group (r = ¡0.108, P =0 . 0 3 3 ) .
Brandi et al. [8] showed that the PPXX genotype of ER
were more frequent in patients with Alzheimer’s disease
(AD), compared to a control group [8]. Estrogen level
decrease is correlated to AD. Estrogen protects neurons.
Estrogen therapy has positive eVects on anxiety–depression
disorder, cognitive malfunction and AD in patients with cli-
macteric syndrome [33]. Depression related to aging may be
a symptom of early-onset AD [8]. The SWAN report found
that 18% of older women have emotional disorders and that
depression was signiWcantly correlated with impaired cogni-
tive function [5]; however, there was no such correlation
between emotional symptoms and cognitive malfunction in
patients with climacteric syndrome [34]. In our study, we
showed that anxiety, depression and somatic symptoms were
negatively correlated with C-MMSE scores in the anxiety–
depression group; however, there was no such correlation in
the control group. Thus, these Wndings are consistent with
SWAN report which suggest cognitive decline correlation
with anxiety and or depression, but not climacteric syn-
drome. There is a negative correlation between the Pp geno-
type in the ER gene and C-MMSE scores, which is
inconsistent with Olsen’s report. In Olsen’s study, the XbaI
genotype XX was negatively correlated with impaired cogni-
tive function in postmenopausal [35]. Recently, Kim et al.
[36] reported similar results. The inconsistent results may be
relation to the diVerence of samples. Is there a correlation
between impaired cognitive function of emotion disorder and
the occurrence of mild cognitive impairment (e.g., MCI or
early-onset AD)? Are the ER polymorphism and decreased
estrogen levels common or diVerent mechanisms in patients
with climacteric syndrome as well as anxiety–depression dis-
orders and patients with AD? These questions need to be fur-
ther investigated in perimenopausal/postmenopausal patients
with anxiety–depression disorders.
Conclusion
The somatic symptoms in patients with climacteric syn-
drome are correlated with emotional disorders but not with
organic diseases. There was no correlation between the
ER allele polymorphism and anxiety or depression symp-
toms, whereas the Pp genotype of the ER Pvu II gene may
be related to impaired cognitive function in patients with
anxiety or depression symptoms.
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